MX2018014185A - Combinacion de antagonistas puros del receptor 5 ht6 con inhibidores de la acetilcolinesterasa. - Google Patents

Combinacion de antagonistas puros del receptor 5 ht6 con inhibidores de la acetilcolinesterasa.

Info

Publication number
MX2018014185A
MX2018014185A MX2018014185A MX2018014185A MX2018014185A MX 2018014185 A MX2018014185 A MX 2018014185A MX 2018014185 A MX2018014185 A MX 2018014185A MX 2018014185 A MX2018014185 A MX 2018014185A MX 2018014185 A MX2018014185 A MX 2018014185A
Authority
MX
Mexico
Prior art keywords
combination
pure
receptor antagonists
acetylcholinesterase inhibitors
adjunct
Prior art date
Application number
MX2018014185A
Other languages
English (en)
Inventor
Jasti Venkateswarlu
Nirogi Ramakrishna
Karbhari Shinde Anil
Jayarajan Pradeep
Bhyrapuneni Gopinadh
Kambhampati Ramasastri
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of MX2018014185A publication Critical patent/MX2018014185A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/305—Mercury compounds
    • A61K31/31—Mercury compounds containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se relaciona con antagonistas puros del receptor 5-HT6, o su(s) sal(es) farmacéuticamente aceptable(s) en combinación con o como adyuvante de inhibidores de la acetilcolinesterasa, y con su uso en el tratamiento de trastornos cognitivos. La invención además provee la composición farmacéutica que contiene dicha combinación.
MX2018014185A 2016-05-18 2016-08-03 Combinacion de antagonistas puros del receptor 5 ht6 con inhibidores de la acetilcolinesterasa. MX2018014185A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201641017205 2016-05-18
PCT/IB2016/054673 WO2017199071A1 (en) 2016-05-18 2016-08-03 Combination of pure 5-ht6 receptor antagonists with acetylcholinesterase inhibitors

Publications (1)

Publication Number Publication Date
MX2018014185A true MX2018014185A (es) 2019-02-25

Family

ID=56940098

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018014185A MX2018014185A (es) 2016-05-18 2016-08-03 Combinacion de antagonistas puros del receptor 5 ht6 con inhibidores de la acetilcolinesterasa.

Country Status (28)

Country Link
US (1) US11458135B2 (es)
EP (1) EP3484467B1 (es)
JP (1) JP6606299B2 (es)
KR (1) KR102015484B1 (es)
CN (2) CN109069468A (es)
AU (1) AU2016407427B2 (es)
BR (1) BR112018073419A2 (es)
CA (1) CA3023819C (es)
CY (1) CY1123013T1 (es)
DK (1) DK3484467T3 (es)
EA (1) EA036347B1 (es)
ES (1) ES2796181T3 (es)
HR (1) HRP20200872T1 (es)
HU (1) HUE050819T2 (es)
IL (1) IL262921B (es)
LT (1) LT3484467T (es)
MA (1) MA45639B1 (es)
MD (1) MD3484467T2 (es)
ME (1) ME03731B (es)
MX (1) MX2018014185A (es)
NZ (1) NZ748280A (es)
PL (1) PL3484467T3 (es)
PT (1) PT3484467T (es)
RS (1) RS60422B1 (es)
SG (1) SG11201809856SA (es)
SI (1) SI3484467T1 (es)
WO (1) WO2017199071A1 (es)
ZA (1) ZA201807468B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111084776A (zh) * 2018-10-24 2020-05-01 中国科学院昆明动物研究所 匹立尼酸及其衍生物用于治疗和/或预防神经退行性疾病的用途
CN111084768A (zh) * 2018-10-24 2020-05-01 中国科学院昆明动物研究所 吉非罗齐及其衍生物用于治疗和/或预防神经退行性疾病的用途
MX2022006535A (es) * 2019-12-02 2022-09-09 Suven Life Sciences Ltd Métodos para tratar síntomas de comportamiento y psicológicos en pacientes con demencia.
US20230000859A1 (en) * 2019-12-02 2023-01-05 Suven Life Sciences Limited Methods for treating behavioral and psychological symptoms in patients with dementia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1581492B1 (en) * 2002-11-28 2008-07-16 Suven Life Sciences Limited N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them
PE20071143A1 (es) 2006-01-13 2008-01-20 Wyeth Corp Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6
ATE509636T1 (de) * 2006-06-23 2011-06-15 Esteve Labor Dr Kombination aus einem cholinesterase-hemmer und einer verbindung mit 5-ht6-rezeptor-affinität
AR061637A1 (es) 2006-06-26 2008-09-10 Epix Delaware Inc Composiciones y metodos de tratamiento de trastornos del snc
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
NZ719671A (en) * 2013-12-02 2017-03-31 Suven Life Sciences Ltd Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate

Also Published As

Publication number Publication date
SI3484467T1 (sl) 2020-10-30
PT3484467T (pt) 2020-06-16
ME03731B (me) 2021-01-20
DK3484467T3 (da) 2020-06-08
EP3484467B1 (en) 2020-04-29
EA201892529A1 (ru) 2019-03-29
IL262921B (en) 2020-05-31
CN109069468A (zh) 2018-12-21
IL262921A (en) 2018-12-31
JP2019516699A (ja) 2019-06-20
RS60422B1 (sr) 2020-07-31
BR112018073419A2 (pt) 2019-03-19
PL3484467T3 (pl) 2020-08-24
WO2017199071A1 (en) 2017-11-23
JP6606299B2 (ja) 2019-11-13
ES2796181T3 (es) 2020-11-26
CA3023819A1 (en) 2017-11-23
ZA201807468B (en) 2020-02-26
CN114642667A (zh) 2022-06-21
LT3484467T (lt) 2020-07-10
MD3484467T2 (ro) 2020-06-30
NZ748280A (en) 2020-07-31
AU2016407427A1 (en) 2018-11-22
AU2016407427B2 (en) 2019-11-21
US20190125743A1 (en) 2019-05-02
SG11201809856SA (en) 2018-12-28
KR20190002700A (ko) 2019-01-08
HRP20200872T1 (hr) 2020-11-27
HUE050819T2 (hu) 2021-01-28
MA45639B1 (fr) 2020-06-30
KR102015484B1 (ko) 2019-08-28
EA036347B1 (ru) 2020-10-29
EP3484467A1 (en) 2019-05-22
CY1123013T1 (el) 2021-10-29
US11458135B2 (en) 2022-10-04
CA3023819C (en) 2019-10-22

Similar Documents

Publication Publication Date Title
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
MX2015011898A (es) Compuestos de pirazolo y usos de los mismos.
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
MX2021002321A (es) Nuevos metodos.
NZ736055A (en) Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
MX2017006437A (es) Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
MY201535A (en) Therapeutic compounds
MX2018014185A (es) Combinacion de antagonistas puros del receptor 5 ht6 con inhibidores de la acetilcolinesterasa.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2020010568A (es) Derivados de urea ciclica fusionada como antagonista de crhr2.
MX2021002322A (es) Nuevos metodos.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2018013969A (es) Combinacion de antagonistas del receptor 5-ht6 puro con un antagonista del receptor nmda.
MX2018014184A (es) Triple combinacion de antagonistas del receptor de 5-ht6 puro, inhibidores de acetilcolinesterasa y antagonista del receptor de nmda.
PH12017501736A1 (en) Indole derivatives
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
MX2018004774A (es) Derivados de morfolina sustituidos que tienen actividad contra el dolor.
NZ750150A (en) Combination of histamine-3 receptor inverse agonists with acetylcholinesterase inhibitors
MX2019001698A (es) Combinacion triple de agonistas inversos del receptor de histamina 3, inhibidores de la acetilcolinestearasa y antagonistas del receptor nmda.
PH12016502107A1 (en) Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
MX2017008497A (es) Nuevos compuestos heterocíclicos y su uso tanto en medicina como en cosmética.
IN2013MU03838A (es)